Poonam Patil, Rutuja Shah, Anwar Shaikh, Smita Nayak, Vaidhun Bhaskar
Poonam Patil, Rutuja Shah, Anwar Shaikh, Smita Nayak, Vaidhun Bhaskar
Anandi Pharmacy College, Kalambe Tarf Kale, Kolhapur.
*Corresponding Author E-mail:
Volume - 12,
Issue - 3,
Year - 2022
Corona virus disease (Covid-19) it had declared an emergency global pandemic1,2,3 that cause terrible effects on respiratory system and killing more than half billion lives.4,5,6 Diabetes has been reported as a risk factor for mucormycosis in 73.5% of cases in India.7 People with diabetes and obesity tend to develop more severe Covid-19 infections. This means they're more expected to take corticosteroids, which are frequently used to treat Covid-19. But the corticosteroids along with diabetes increase the risk of mucormycosis because it has been observed that peoples are affected with mucormycosis due to weekend immunity. Even a short course of steroid (5-14 days) results in mucormycosis.8 Mucormycosis, colloquially known as black fungus, is an infection from the mucormycetes group of fungi. The virus that causes Covid-19 can damage lung tissue and blood vessels, which could also increase susceptibility to different fungal infection. brain, causing headaches or seizures. So, damage to tissue and blood vessels from Covid-19 infection, treatment with corticosteroids, high background rates of diabetes in the population most brutally affected by the coronavirus are also getting affected by life threating fungal infection called as mucormycosis. Several methods have deferred the mortality but still have a challenge in curing mucorales.
Cite this article:
Poonam Patil, Rutuja Shah, Anwar Shaikh, Smita Nayak, Vaidhun Bhaskar. Post covid calamity- Mucormycosis: An overview. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(3):227-0. doi: 10.52711/2231-5659.2022.00040
Poonam Patil, Rutuja Shah, Anwar Shaikh, Smita Nayak, Vaidhun Bhaskar. Post covid calamity- Mucormycosis: An overview. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(3):227-0. doi: 10.52711/2231-5659.2022.00040 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2022-12-3-12
1. Poonam Patil Critical Mobility And Inclination For Covid-19; 2020 9 (4) A; April 2020; Page No. 21803-21805.
2. Princy Louis Palatty Sathyajith G. A review Pharmacotherapy for COVID-19. Asian Journal of Pharmacy and Pharmacology 2020; 6(5): 320-329.
3. Mayur S. Jain, Shashikant D. Barhate. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19: A Review. 10.5958/2231-5691.2021.00008.3.
4. B. V. Naresh. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian J. Pharm. Res. 2020; 10(3):233-238.
5. Archana B. Chavhan, Pavan S. Jadhav, Satish Shelke. COVID 19: Outbreak, Structure and Current therapeutic strategies. Asian J. Pharm. Tech. 2021; 11(1):76-83.
6. Ali Adel dawood. Should we worry that the COVID-19 could be transmitted with the semen?. Asian J. Pharm. Res. 2020; 10(4):319-320.
7. Patel, A.; Kaur, H.; Xess, I.; Michael, J.S.; Savio, J.; Rudramurthy, S.; Singh, R.; Shastri, P.; Umabala, P.;Sardana, R. A multicenter observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. Microbiol. Infect. 2020, 26, 944.e9–944.e15. [CrossRef] [PubMed]
8. Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep. 2020;29(1):22-24.
9. Kubin CJ, McConville TH, Dietz D, et al. Characterization of Bacterial and Fungal Infections in Hospitalized Patients with COVID-19 and Factors Associated with Healthcare-associated Infections, Open Forum Infectious Diseases, 2021;,of ab 201, https://doi.org/10.1093/ofid/ofab201.
10. Vankadari Venkata Sesha Satya Sagar1,Pallavi Yelne Mucormycosis in RT-PCR negative Covid 19 patient with newly diagnosed Diabetes Mellitus: A Case Report Asian Journal of Medical Sciences 2021 12 (7) 149-153.
11. Ukpe Ajima A review of the Structure-Activity Relationships (SAR) of selected drugs with potential to be repurposed against SARS-COV-2 Asian Journal of Pharmacy and Pharmacology 2021; 7(1): 38-46.
12. Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020 Aug;185(4):599-606.
13. Savita Ramesh Shahani, Lokesh R. Shahani: COVID-19 infection: Does BCG Vaccine offers any protection. Asian Journal of Pharmacy and Pharmacology 2020; 6(3): 183-189.
14. Baker RD. Pulmonary mucormycosis. Am J Pathol 1956; 32:287–313.
15. Baker RD. Mucormycosis, a new disease? JAMA 1957; 163:805–8.
16. B. Spellberg, T. J. Walsh, D. P. Kontoyiannis, J. J. Edwards Jr., and A. S. Ibrahim, “Recent advances in the management of mucormycosis: from bench to bedside,” Clinical Infectious Diseases, vol. 48, no. 12, pp. 1743–1751, 2009
17. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposureexternal icon. Clin Microbiol Infect. 2009 Oct;15 Suppl 5:2-9.
18. Al-Ajam, MR, Bizri, AR, Mokhbat, J, Weedon, J, Lutwick, L. Mucormycosis in the Eastern Mediterranean: a seasonal diseaseexternal icon. Epidemiol Infect. 2006 Apr 134(2):341-6.
19. Sivagnanam, S, Sengupta, DJ, Hoogestraat, D, Jain, R, Stednick, Z, Fredricks, DN, et al. Seasonal clustering of sinopulmonary mucormycosis in patients with hematologic malignancies at a large comprehensive cancer centerexternal icon. Antimicrob Resist Infect Control. 2017 November;6(1).
20. Alvarez E, Sutton DA, Cano J, et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol 2009; 47:1650–6
21. Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infect. 2020;
22. Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, Chen J. Mucormycosis in renal transplant recipients: review of 174 reported casesexternal icon. BMC Infect Dis. 2017 Apr; 17(1): 283.
23. Abdalla A, Adelmann D, Fahal A, Verbrugh H, Van Belkum A, De Hoog S. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudanexternal icon. J Clin Microbiol. 2002 Mar; 40(3): 1031–1036.
24. Vallabhaneni S, Mody RK. Gastrointestinal mucormycosis in neonates: a reviewexternal icon. Current Fungal Infect Rep. 2015.
25. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosisexternal icon. Clin Infect Dis. 2012 Feb;54 Suppl 1:S23-34.
26. Rauthan P, Sharma DC, Mucormycosis: Pathogenesis, Diagnosis, and Management, Asian Journal of Pharmaceutical Research and Development. 2021; 9(3):144-153.
27. Francis JR, Villanueva P, Bryant P, Blyth CC. Mucormycosis in children: review and recommendations for managementexternal icon. J Pediatric Infect Dis Soc. 2018 May 15;7(2):159-164.
28. Bassetti M, Bouza E. Invasive mould infections in the ICU setting:complexities and solutions. J Antimicrob Chemother. 2017;72(1):i39–i47. doi:10.1093/jac/dkx032.
29. Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features and outcomes. Infect. 2017;45(4):443–8. doi:10.1007/s15010-017-0991-6.
30. Crum-Cianflone NF. Mucormycosis. eMedicine. 2008.
31. Deutsch PG, Whittaker J, Prasad S. Invasive and non-invasive fungal rhinosinusitis—a review and update of the evidence, Medicina 55 (2019) 1–14.
32. Ribes JA, Vanover-Sams CL, Baker DJ: Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13(2): 236–301.
33. Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5): 634–53.
34. Baldin C, Ibrahim AS: Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathog. 2017; 13(8): e1006408.
35. Momeni AK, Roberts CC, Chew FS. Imaging of chronic and exotic sinonasal disease: review. AJR Am J Roentgenol 2007;189(6): S35–45. https://doi.org/10.2214/ AJR.07.7031
36. Gokulshankar S, Mohanty BK COVID-19 AND BLACK FUNGUS. Asian Journal of Medicine and Health Sciences 2021 4 (1) 137-140.
37. Deutsch PG, Whittaker J, Prasad S. Invasive and non-invasive fungal rhinosinusitis-a review and update of the evidence, Medicina 55 (2019) 1–14.
38. Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.M.; Chen, S.C.A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019, 25, 26–34. [CrossRef] [PubMed]
39. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematological, 2013; 98(4): 492-504.